Promising novel cytotoxic agents and combinations in metastatic prostate cancer

Deborah A. Bradley, Maha Hussain*

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Interest in investigating cytotoxic therapy has increased dramatically since a survival advantage was demonstrated in 2 phase III trials investigating docetaxel-based therapy in hormone-refractory prostate cancer. This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents.

Original languageEnglish (US)
Pages (from-to)15-19
Number of pages5
JournalCancer Journal
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2008

Keywords

  • Chemotherapy
  • Cytotoxic therapy
  • Hormone-refractory prostate cancer
  • Metastatic
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Promising novel cytotoxic agents and combinations in metastatic prostate cancer'. Together they form a unique fingerprint.

  • Cite this